Immunotoxic and hepatotoxic effects of perfluoro-n-decanoic acid (PFDA) on female Harlan Sprague-Dawley rats and B6C3F1/N mice when administered by oral gavage for 28 days. 2018

Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
a Division of the National Toxicology Program , National Institute of Environmental Health Sciences , Research Triangle Park , NC , USA.

Poly- and perfluoroalkyl substances (PFAS) are chemically and thermally stable, hydrophobic, lipophobic compounds used in stain repellants and water and oil surfactants, and associated with immunosuppression and peroxisome proliferator activity. Perfluoro-n-decanoic acid (PFDA, (CF3(CF2)8COOH), a fluorinated straight chain fatty acid compound, is reported to induce thymic atrophy and reversible bone marrow hypocellularity in rodent models. The objective of this study was to assess potential immunotoxicity of PFDA, due to its structural similarity to other immunosuppressive PFASs. Female Harlan Sprague-Dawley rats were exposed to 0-2.0 mg PFDA/kg by oral gavage daily for 28 d. Female B6C3F1/N mice were exposed once/week to 0-5.0 mg PFDA/kg by gavage for 4 weeks. Animals were evaluated for effects on immune cell populations in spleen and bone marrow, and innate, humoral-, and cell-mediated immunity. Mice were also evaluated for resistance to Influenza virus. Treatment-related hepatocyte necrosis and hepatomegaly were observed in rats treated with 0.5 mg PFDA/kg/d. In mice, hepatomegaly (26-89%) was observed following exposure to ≥0.625 mg PFDA/kg/week, while splenic atrophy (20%) was observed at 5.0 mg PFDA/kg/week. At 5.0 mg PFDA/kg/week, total spleen cells, and Ig + and NK + cells were decreased (17.6-27%). At ≥ 1.25 mg PFDA/kg/week the numbers of splenic CD3+, CD4+, CD8+, and Mac3+ cells were decreased (10.5-39%). No changes were observed in leukocyte subpopulations in PFDA-exposed rats. Phagocytosis by fixed-tissue macrophages was decreased in liver (specific activity, 24-39%) at ≥0.25 mg PFDA/kg/d in rats. PFDA-induced effects on humoral- and cell-mediated immunity, host resistance, and bone marrow progenitor cells were limited. These data suggest that exposure to PFDA may induce adverse effects in rat liver in a manner consistent with the PFAS class, and may also alter the balance of immune cell populations in lymphoid tissues in mice.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D009975 Orthomyxoviridae A family of RNA viruses causing INFLUENZA and other respiratory diseases. Orthomyxoviridae includes INFLUENZAVIRUS A; INFLUENZAVIRUS B; INFLUENZAVIRUS C; INFLUENZAVIRUS D; ISAVIRUS; and THOGOTOVIRUS. Influenza Viruses,Myxoviruses,Orthomyxoviruses,Influenza Virus,Myxovirus,Orthomyxovirus
D009976 Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE. Orthomyxovirus Infections,Infections, Orthomyxoviridae,Infections, Orthomyxovirus,Swine Influenza,Infection, Orthomyxoviridae,Infection, Orthomyxovirus,Influenza, Swine,Orthomyxoviridae Infection,Orthomyxovirus Infection
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003652 Decanoic Acids 10-carbon saturated monocarboxylic acids. Capric Acids,Acids, Capric,Acids, Decanoic

Related Publications

Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
January 2021, Toxicology reports,
Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
June 2020, Toxicity report series,
Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
January 1988, Journal of toxicology and environmental health,
Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
December 2012, Xenobiotica; the fate of foreign compounds in biological systems,
Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
December 2023, National Toxicology Program technical report series,
Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
July 2017, National Toxicology Program technical report series,
Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
November 2018, Xenobiotica; the fate of foreign compounds in biological systems,
Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
November 2018, Xenobiotica; the fate of foreign compounds in biological systems,
Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
March 2021, Toxicity report series,
Rachel P Frawley, and Matthew Smith, and Mark F Cesta, and Schantel Hayes-Bouknight, and Chad Blystone, and Grace E Kissling, and Shawn Harris, and Dori Germolec
February 2000, Toxicity report series,
Copied contents to your clipboard!